Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.

Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA

Diabetes care7 Oct 2010Cited by 183 (Europe PMC)

PMID20929995PMCIDPMC3005487DOI10.2337/dc10-1393PepBankPUB-20929995

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide use was linked to lower CVD event risk than other glucose-lowering therapies.
In plain wordsIn patients with type 2 diabetes, exenatide was linked to fewer cardiovascular events than other blood sugar treatments.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCardiovascular disease events
Study
n: not reported in source
Comparator
other glucose-lowering therapies
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
twice dailyAs given in this study (human).
Measurements
Hazard ratio
0.81 unitless
CVD events
95% CI
0.68 to 0.95 unitless
CVD hazard ratio
Source sentences
Summary
Exenatide-treated patients were less likely to have a CVD event than non-exenatide-treated patients (hazard ratio 0.81; 95% CI 0.68-0.95; P = 0.01) and lower rates of CVD-related hospitalization (0.88; 0.79-0.98; P = 0.02) and all-cause hospitalization (0.94; 0.91-0.97; P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective database analysis was performed of the LifeLink database of medical and pharmaceutical insurance claims for June 2005 through March 2009.
Summary · context
Patients with no history in the preceding 9 months of myocardial infarction, ischemic stroke, or coronary revascularization procedure were assigned to the exenatide-initiated or non-exenatide-initiated cohorts based on the first new prescription filled and reassigned if exenatide was prescribed or discontinued.
Summary · context
Patient outcomes were adjusted for differences in clinical and demographic characteristics and compared using propensity score-weighted discrete time survival analysis with time-varying exposure to exenatide.
Report a problemFND-2092999501
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide use was linked to fewer CVD-related hospitalizations than other glucose-lowering therapies.
In plain wordsIn patients with type 2 diabetes, exenatide was linked to fewer cardiovascular hospitalizations than other blood sugar treatments.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCVD-related hospitalization
Study
n: not reported in source
Comparator
other glucose-lowering therapies
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
twice dailyAs given in this study (human).
Measurements
Hazard ratio
0.88 unitless
CVD-related hospitalization
95% CI
0.79 to 0.98 unitless
CVD hospitalization hazard ratio
Source sentences
Summary
Exenatide-treated patients were less likely to have a CVD event than non-exenatide-treated patients (hazard ratio 0.81; 95% CI 0.68-0.95; P = 0.01) and lower rates of CVD-related hospitalization (0.88; 0.79-0.98; P = 0.02) and all-cause hospitalization (0.94; 0.91-0.97; P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective database analysis was performed of the LifeLink database of medical and pharmaceutical insurance claims for June 2005 through March 2009.
Summary · context
Patients with no history in the preceding 9 months of myocardial infarction, ischemic stroke, or coronary revascularization procedure were assigned to the exenatide-initiated or non-exenatide-initiated cohorts based on the first new prescription filled and reassigned if exenatide was prescribed or discontinued.
Summary · context
Patient outcomes were adjusted for differences in clinical and demographic characteristics and compared using propensity score-weighted discrete time survival analysis with time-varying exposure to exenatide.
Report a problemFND-2092999502
03HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide use was linked to fewer all-cause hospitalizations than other glucose-lowering therapies.
In plain wordsIn patients with type 2 diabetes, exenatide was linked to fewer hospitalizations than other blood sugar treatments.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAll-cause hospitalization
Study
n: not reported in source
Comparator
other glucose-lowering therapies
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
twice dailyAs given in this study (human).
Measurements
Hazard ratio
0.94 unitless
all-cause hospitalization
95% CI
0.91 to 0.97 unitless
all-cause hospitalization hazard ratio
Source sentences
Summary
Exenatide-treated patients were less likely to have a CVD event than non-exenatide-treated patients (hazard ratio 0.81; 95% CI 0.68-0.95; P = 0.01) and lower rates of CVD-related hospitalization (0.88; 0.79-0.98; P = 0.02) and all-cause hospitalization (0.94; 0.91-0.97; P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A retrospective database analysis was performed of the LifeLink database of medical and pharmaceutical insurance claims for June 2005 through March 2009.
Summary · context
Patients with no history in the preceding 9 months of myocardial infarction, ischemic stroke, or coronary revascularization procedure were assigned to the exenatide-initiated or non-exenatide-initiated cohorts based on the first new prescription filled and reassigned if exenatide was prescribed or discontinued.
Summary · context
Patient outcomes were adjusted for differences in clinical and demographic characteristics and compared using propensity score-weighted discrete time survival analysis with time-varying exposure to exenatide.
Report a problemFND-2092999503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02251431

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

Baylor Research Instituten = 57Nov 2015 to Dec 2019

Type 2 Diabetes Mellitus · Chronic Kidney Disease · Left Ventricular Diastolic Dysfunction

Trial page ClinicalTrials.govUpdated 19 Feb 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.